secwatch.observer — SEC 8-K summary
======================================

Issuer:     Trevi Therapeutics, Inc. (TRVI)
CIK:        0001563880
Form:       8-K
Filed at:   2023-03-16T23:59:59+00:00
Accession:  0000950170-23-008459
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Trevi Therapeutics reports Q4 2022 net loss $5.5M; cash $120.5M into 2026
-------------------------------------------------------------------------

- Net loss Q4 2022: $5.5M ($0.05 per share) vs $8.5M loss same period 2021. Full-year loss $29.2M vs $33.9M.
- Cash, equivalents, and marketable securities $120.5M; expects cash runway into 2026.
- Plans Phase 2b dose-ranging trial of Haduvio for IPF chronic cough in H2 2023; Phase 1b respiratory study also H2 2023.
- Phase 2a trial in refractory chronic cough expected to start Q3 2023.
- Open-label extension data from Phase 2b/3 PRISM trial in prurigo nodularis expected Q2 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/0000950170-23-008459-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1563880/000095017023008459/trvi-20230316.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-008459

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer